Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.64 |
| ▸ | NT5E | P21589 | 2/20 | 0.62 |
| ▸ | SLC29A1 | Q99808 | 6/20 | 0.61 |
| ▸ | PGK1 | P00558 | 1/20 | 0.59 |
| ▸ | PGK2 | P07205 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7100664 | 0.92 | LMNA (0.78) | CYP2C19LMNATP53ADORA3ADORA1 | |
| SCHEMBL637420 | 0.92 | LMNA (0.78) | CYP2C19LMNATP53ADORA3ADORA1 | |
| SCHEMBL14928763 | 0.92 | LMNA (0.78) | CYP2C19LMNATP53ADORA3ADORA1 | |
| SCHEMBL23680013 | 0.92 | LMNA (0.78) | CYP2C19LMNATP53ADORA3ADORA1 | |
| SCHEMBL14853642 | 0.92 | LMNA (0.78) | CYP2C19LMNATP53ADORA3ADORA1 | |
| SCHEMBL637421 | 0.92 | LMNA (0.78) | CYP2C19LMNATP53ADORA3ADORA1 | |
| SCHEMBL14163069 | 0.92 | LMNA (0.78) | CYP2C19LMNATP53ADORA3ADORA1 | |
| SCHEMBL12987511 | 0.92 | LMNA (0.78) | CYP2C19LMNATP53ADORA3ADORA1 | |
| SCHEMBL18464460 | 0.92 | LMNA (0.78) | CYP2C19LMNATP53ADORA3ADORA1 | |
| SCHEMBL30495908 | 0.92 | LMNA (0.78) | CYP2C19LMNATP53ADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021511-B2 | Cyclic dinucleotides as sting agonists | JANSSEN BIOTECH, INC. (US) | 2021-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021511-B2 | Cyclic dinucleotides as sting agonists | STING1, CGAS, MAVS | CYP2C19 4145/4885LMNA 630/4885TP53 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.